GlassScriptPhysician profile
James C Wilson
NPI 1285622365
$4,016.05
in general payments reported to CMS, 2019-2025
32 companies · $1,949 in 2025
The $1,949 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.13 · 2022: $173 · 2023: $911 · 2024: $965 · 2025: $1,949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,718 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,718.32 |
| Education | $107.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,081.22 | 2022-2025 | Rexulti |
| Abbvie INC. | $798.58 | 2022-2025 | Qulipta, Vraylar, Mavyret |
| Lilly USA, LLC | $260.52 | 2023-2025 | Kisunla, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $241.79 | 2023-2025 | Airsupra |
| Vanda Pharmaceuticals INC. | $206.72 | 2025 | Fanapt |
| Corium, LLC | $199.80 | 2023-2024 | Azstarys |
| Abbott Laboratories | $187.37 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $127.14 | 2024-2025 | Voquezna |
| Indivior INC. | $124.87 | 2025 | Sublocade |
| Gilead Sciences, INC. | $88.03 | 2023-2025 | |
| Novo Nordisk INC | $83.71 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Paratek Pharmaceuticals, INC. | $79.47 | 2024-2025 | Nuzyra, Xhance |
| Janssen Pharmaceuticals, INC | $73.64 | 2024-2025 | Spravato |
| Neurocrine Biosciences, INC. | $59.52 | 2024-2025 | Ingrezza |
| Ardelyx, INC. | $50.21 | 2024-2025 | Ibsrela |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $34.60 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Inogen, INC. | $33.29 | 2025 | |
| Corcept Therapeutics | $27.49 | 2024 | Korlym |
| Scpharmaceuticals INC. | $26.88 | 2024 | |
| Verona Pharma, INC. | $24.74 | 2025 | Ohtuvayre |
| Braeburn INC. | $24.47 | 2025 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.10 | 2025 | Caplyta |
| Pfizer INC. | $22.70 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $16.95 | 2025 | Austedo Xr |
| Viatris Specialty LLC | $16.93 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $16.01 | 2023 | |
| Amgen INC. | $15.71 | 2025 | Otezla, Repatha |
| Valinor Pharma, LLC | $14.98 | 2024 | Movantik |
| Acella Pharmaceuticals, LLC | $13.97 | 2024 | NP Thyroid 60 |
| Axsome Therapeutics, INC. | $13.84 | 2025 | Auvelity |
| Alkermes, INC. | $13.52 | 2023 | Aristada, Lybalvi |
| Kowa Pharmaceuticals America, INC. | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.